Within tarantula venom, new hope for safe and novel painkillers found
Screening more than 100 spider toxins, Yale researchers identified a protein from the venom of the Peruvian green velvet tarantula that blunts activity in pain-transmitting neurons. The findings, reported in the March 3 issue of the journal Current Biology, show the new screening method used by the scientists has the potential to search millions of different spider toxins for safe pain-killing drugs and therapies.
Our recent TRPA1 toxineering paper, led by Junhong Gui, has been covered by the New York Times.
"Toxineering," a new method developed by investigators at the Kavli Institute for Neuroscience at Yale, may be used to screen millions of spider toxins for safe pain-killing drugs and therapies. With it, Michael Nitabach and his colleagues have identified a protein from the venom of the Peruvian green velvet tarantula that targets an ion channel linked to neuropathic pain.Source: The New York Times
Lighting a new path to understanding the 'language' of the brain
School of Medicine researchers have developed a new technique that allows them to non-invasively and simultaneously measure electrical activity in many neurons in a living organism, a prerequisite for understanding the complex language of the brain. The technique, described in the Aug. 8 issue of the journal Cell, involves inserting a fluorescent protein that varies in intensity in response to changes in electrical signals into neurons and recording the changing light with optical sensors.
Comparative effectiveness of group v. individual trauma-focused treatment for posttraumatic stress disorder in veterans
Group cognitive processing therapy (CPT) was associated with a slightly smaller reduction of PTSD symptom severity than individual CPT or prolonged exposure (PE) in veterans at the end of residential treatment. There were no differences at 4-month follow-up.Source: Psychological Medicine
Griffith Receives Cato T. Laurencin M.D., Ph.D. Lifetime Research Award at National Medical Association Event
Ezra Griffith, MD, professor emeritus of psychiatry, was recently honored with the Cato T. Laurencin MD, PhD Lifetime Research Award, the highest annual research award given by the W. Montague Cobb/NMA Health Institute.Source: EIN Presswire
Association of Distress Due to Systemic Racism and Racial Disparities With Psychopathology and Suicidal Ideation Among US Veterans During the COVID-19 Pandemic
A team of Yale Psychiatry researchers analyzed data from a national sample of US veterans to examine the prevalence of perceived systemic racism and racial disparities in COVID-19–related health outcomes and the association of racism-related distress with internalizing and externalizing psychopathology and suicidal ideation during the pandemic.Source: The Journal of Clinical Psychiatry
Fortunati Talks About Heat Impact on Mental Health
Frank Fortunati, MD, JD, Frank Fortunati, MD, JD, assistant professor of psychiatry at Yale School of Medicine and associate chief of psychiatry at Yale New Haven Hospital spoke with NBC Connecticut about the impact of heat on mental health.Source: NBC Connecticut
Yale Scientists Identify Genetic Risk Factors for Opioid Use and Related Substance Use Disorders
A new human genomics study led by Yale scientists has identified genetic risk factors for opioid use disorder (OUD) and related substance use disorders according to a new large-scale genome-wide association study – increasing the number of risk genes known from 1 to 19.
Pharmacy Deserts: More Than Where Pharmacies Are
Walter S. Mathis, MD, assistant professor of psychiatry, is senior author of a paper in Journal of the American Pharmacists Association that assesses pharmacy deserts using travel time rather than distance from a person's home.Source: Journal of the American Pharmacists Association
Yale Study: Opioid Tapering Support Using a Web-based App
Sara N. Edmond, PhD, assistant professor of psychiatry, is first author of a paper in Contemporary Clinical Trials that describes the development and protocols of a web-based program designed to support patients willing to consider an opioid taper.Source: Contemporary Clinical Trials